Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Front Pediatr ; 10: 909176, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-35967550

RESUMO

Antimicrobial polypeptides (APPs) are part of the innate immune system, but their specific role in the context of preterm birth is not yet understood. The aim of this investigation was to determine the systemic expression of APPs, i.e., lactoferrin (LF) and human neutrophil protein (HNP) 1-3 in preterm infants in the period of highest vulnerability for infection and to correlate these biomarkers with short-term outcome. We therefore conducted a prospective two-center study including plasma samples of 278 preterm infants and 78 corresponding mothers. APP levels were analyzed on day 1, 3, 7, and 21 of life via enzyme-linked immunosorbent assay (ELISA). The levels of LF and HNP1-3 remained stable during the first 21 days of life and were not influenced by maternal levels. Elevated APP levels were found at day 1 in infants born to mothers with amniotic infection syndrome (AIS vs. no AIS, mean ± SD in ng/ml: LF 199.8 ± 300 vs. 124.1 ± 216.8, HNP 1-3 16,819 ± 36,124 vs. 8,701 ± 11,840; p = 0.021, n = 179). We found no elevated levels of APPs before the onset of sepsis episodes or in association with other short-term outcomes that are in part mediated by inflammation such as necrotizing enterocolitis (NEC) or retinopathy of prematurity (ROP). Interestingly, infants developing bronchopulmonary dysplasia (BPD) showed higher levels of HNP1-3 on day 21 than infants without BPD (13,473 ± 16,135 vs. 8,388 ± 15,938, n = 111, p = 0.008). In infants born without amniotic infection, levels of the measured APPs correlated with gestational age and birth weight. In our longitudinal study, systemic levels of LF and HNP 1-3 were not associated with postnatal infection and adverse short-term outcomes in preterm infants.

2.
Clin Case Rep ; 9(7): e04527, 2021 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-34306701

RESUMO

The delineation of the prenatal diagnostic key features of PIK3CA-related overgrowth spectrum disorders will assume a crucial part in future and a prenatal diagnosis of the causing mutations would provide physicians with a simplified interdisciplinary perinatal management.

3.
PLoS Genet ; 17(6): e1009619, 2021 06.
Artigo em Inglês | MEDLINE | ID: mdl-34161347

RESUMO

Lysosome-associated membrane glycoprotein 3 (LAMP3) is a type I transmembrane protein of the LAMP protein family with a cell-type-specific expression in alveolar type II cells in mice and hitherto unknown function. In type II pneumocytes, LAMP3 is localized in lamellar bodies, secretory organelles releasing pulmonary surfactant into the extracellular space to lower surface tension at the air/liquid interface. The physiological function of LAMP3, however, remains enigmatic. We generated Lamp3 knockout mice by CRISPR/Cas9. LAMP3 deficient mice are viable with an average life span and display regular lung function under basal conditions. The levels of a major hydrophobic protein component of pulmonary surfactant, SP-C, are strongly increased in the lung of Lamp3 knockout mice, and the lipid composition of the bronchoalveolar lavage shows mild but significant changes, resulting in alterations in surfactant functionality. In ovalbumin-induced experimental allergic asthma, the changes in lipid composition are aggravated, and LAMP3-deficient mice exert an increased airway resistance. Our data suggest a critical role of LAMP3 in the regulation of pulmonary surfactant homeostasis and normal lung function.


Assuntos
Células Epiteliais Alveolares/metabolismo , Asma/genética , Homeostase/genética , Proteína 3 de Membrana Associada ao Lisossomo/genética , Proteína C Associada a Surfactante Pulmonar/genética , Surfactantes Pulmonares/metabolismo , Resistência das Vias Respiratórias , Células Epiteliais Alveolares/patologia , Animais , Asma/induzido quimicamente , Asma/metabolismo , Asma/patologia , Líquido da Lavagem Broncoalveolar , Modelos Animais de Doenças , Feminino , Edição de Genes/métodos , Regulação da Expressão Gênica , Lipidômica , Pulmão/metabolismo , Pulmão/patologia , Proteína 3 de Membrana Associada ao Lisossomo/deficiência , Camundongos , Camundongos Knockout , Ovalbumina/administração & dosagem , Isoformas de Proteínas/genética , Isoformas de Proteínas/metabolismo , Alvéolos Pulmonares/metabolismo , Alvéolos Pulmonares/patologia , Proteína C Associada a Surfactante Pulmonar/metabolismo , Testes de Função Respiratória , Transdução de Sinais
4.
Crit Care Med ; 37(5): 1750-6, 2009 May.
Artigo em Inglês | MEDLINE | ID: mdl-19325472

RESUMO

OBJECTIVE: Surface activity of pulmonary surfactant is impaired by exposure to syringes lubricated with silicone oil (SO). These syringes are used daily in clinical practice. DESIGN: In vitro experiments were used for detection of SO, determination of surface activity, and semiquantitative measurement of surfactant protein (SP)-B and -C in SO/surfactant mixtures. Randomized, controlled animal studies were applied for determination of in vivo activity. SETTING: University research laboratory. INTERVENTIONS: Mass spectrometry of SO originating from syringes with and without surfactant was performed. The surface activity of SO plus surfactant phospholipids (PLs) or modified natural surfactant (Curosurf) was measured. SO/Curosurf preparations were further analyzed for changes in the content of SP-B and SP-C using immunoblotting. Neonatal rabbits received mixtures of SO/Curosurf (ratio 0-1.3 mg/mg PL) intratracheally and were then ventilated with a standardized sequence of peak insufflation pressures. Tidal volume curves were recorded, gas volumes of excised lungs were measured, and histologic analysis was performed. MEASUREMENTS AND MAIN RESULTS: Dissolved SO was found after rinsing syringes with organic solvents or Curosurf. Surface activity of Curosurf was significantly reduced after addition of 0.13-1.3 mg SO/mg PL. Immunoblotting revealed interference of SO with SP-B, but not with SP-C. With increasing SO/Curosurf ratios, patchy alveolar air expansion was observed, lung gas volumes were reduced, and time to inflate the lungs was increased, whereas compliance and tidal volumes remained unimpaired. CONCLUSIONS: In vitro SO impairs surface activity of Curosurf and leads to interference with SP-B. SO contamination of exogenous surfactant impairs lung function in animal studies and should be avoided.


Assuntos
Proteína B Associada a Surfactante Pulmonar/metabolismo , Surfactantes Pulmonares/metabolismo , Óleos de Silicone/farmacologia , Análise de Variância , Animais , Animais Recém-Nascidos , Western Blotting , Modelos Animais de Doenças , Técnicas In Vitro , Complacência Pulmonar , Espectrometria de Massas , Probabilidade , Troca Gasosa Pulmonar , Proteína B Associada a Surfactante Pulmonar/efeitos dos fármacos , Coelhos , Distribuição Aleatória , Respiração Artificial , Sensibilidade e Especificidade , Estatísticas não Paramétricas , Tensão Superficial , Volume de Ventilação Pulmonar
5.
J Appl Physiol (1985) ; 104(4): 1101-8, 2008 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-18276900

RESUMO

Modified natural surfactant preparations, used for treatment of respiratory distress syndrome in premature infants, contain phospholipids and the hydrophobic surfactant protein (SP)-B and SP-C. Herein, the individual and combined effects of SP-B and SP-C were evaluated in premature rabbit fetuses treated with airway instillation of surfactant and ventilated without positive end-expiratory pressure. Artificial surfactant preparations composed of synthetic phospholipids mixed with either 2% (wt/wt) of porcine SP-B, SP-C, or a synthetic poly-Leu analog of SP-C (SP-C33) did not stabilize the alveoli at the end of expiration, as measured by low lung gas volumes of approximately 5 ml/kg after 30 min of ventilation. However, treatment with phospholipids containing both SP-B and SP-C/SP-C33 approximately doubled lung gas volumes. Doubling the SP-C33 content did not affect lung gas volumes. The tidal volumes were similar in all groups receiving surfactant. This shows that SP-B and SP-C exert different physiological effects, since both proteins are needed to establish alveolar stability at end expiration in this animal model of respiratory distress syndrome, and that an optimal synthetic surfactant probably requires the presence of mimics of both SP-B and SP-C.


Assuntos
Animais Recém-Nascidos/fisiologia , Alvéolos Pulmonares/fisiologia , Proteína B Associada a Surfactante Pulmonar/fisiologia , Proteína C Associada a Surfactante Pulmonar/fisiologia , Síndrome do Desconforto Respiratório do Recém-Nascido/fisiopatologia , 1,2-Dipalmitoilfosfatidilcolina/farmacologia , Sequência de Aminoácidos , Animais , Feminino , Humanos , Recém-Nascido , Medidas de Volume Pulmonar , Dados de Sequência Molecular , Fosfolipídeos/metabolismo , Respiração com Pressão Positiva , Gravidez , Surfactantes Pulmonares/farmacologia , Coelhos , Mecânica Respiratória/fisiologia , Volume de Ventilação Pulmonar/fisiologia
6.
Neonatology ; 92(3): 194-200, 2007.
Artigo em Inglês | MEDLINE | ID: mdl-17476119

RESUMO

BACKGROUND: Modified natural surfactants currently used for treatment of respiratory distress syndrome contain about 0.5-1% (w/w phospholipids) of each of the surfactant proteins SP-B and SP-C. The supply of these preparations is limited and synthetic surfactant preparations containing lipids and peptides are under development. OBJECTIVES: To investigate the potential of different concentrations of the SP-C analogue SP-C33 in 1,2-dipalmitoyl-sn-glycero-3-phosphocholine/1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol (68:31, w/w). METHODS: Surface activity was evaluated in pulsating and captive bubble surfactometers and in immature newborn rabbits. RESULTS: Preparations containing >or=1% SP-C33 achieve minimum surface tension <5 mN/m indicating good biophysical activity, and increase tidal volumes in premature rabbit fetuses to the same level as a modified natural surfactant preparation does. Alveolar patency at end expiration, as evaluated by measurement of lung gas volumes, histological assessment of alveolar expansion and determination of alveolar volume density, was lower in the animals treated with synthetic surfactant than in those receiving modified natural surfactant. CONCLUSIONS: These data suggest that SP-C33 is similarly efficient as the native peptide in improving surface properties of phospholipids mixtures and in increasing lung compliance in surfactant-deficient states, but that other components are needed to maintain alveolar stability at low airway pressures.


Assuntos
Pulmão/efeitos dos fármacos , Fosfatidilcolinas/farmacologia , Fosfatidilgliceróis/farmacologia , Proteína C Associada a Surfactante Pulmonar/farmacologia , Animais , Animais Recém-Nascidos , Relação Dose-Resposta a Droga , Fluxo Expiratório Forçado/efeitos dos fármacos , Fluxo Expiratório Forçado/fisiologia , Técnicas In Vitro , Pulmão/patologia , Pulmão/fisiopatologia , Alvéolos Pulmonares/efeitos dos fármacos , Alvéolos Pulmonares/patologia , Coelhos , Respiração Artificial , Tensão Superficial/efeitos dos fármacos , Volume de Ventilação Pulmonar/efeitos dos fármacos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA